Zentalis Pharmaceuticals (NASDAQ:ZNTL) Sees Strong Trading Volume
Zentalis Pharmaceuticals (NASDAQ:ZNTL) Sees Strong Trading Volume
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) shares saw an uptick in trading volume on Wednesday . 32,512 shares were traded during mid-day trading, a decline of 95% from the previous session's volume of 637,692 shares.The stock last traded at $24.20 and had previously closed at $26.45.
納斯達克(代碼:ZNTL-GET Rating)的股票週三成交量有所上升。午盤成交量為32,512股,較前一交易日的637,692股下降95%。該股尾盤報24.20美元,此前收盤報26.45美元。
Analysts Set New Price Targets
分析師設定新的價格目標
A number of brokerages recently weighed in on ZNTL. SVB Leerink reduced their target price on Zentalis Pharmaceuticals from $67.00 to $42.00 and set an "outperform" rating on the stock in a report on Wednesday, August 10th. Morgan Stanley reduced their target price on Zentalis Pharmaceuticals from $95.00 to $60.00 and set an "overweight" rating on the stock in a report on Thursday, August 11th. Cowen began coverage on Zentalis Pharmaceuticals in a research report on Tuesday, July 12th. They issued an "outperform" rating on the stock. Cowen began coverage on Zentalis Pharmaceuticals in a research report on Tuesday, July 12th. They issued an "outperform" rating on the stock. Finally, Guggenheim cut their price objective on Zentalis Pharmaceuticals to $57.00 and set a "na" rating on the stock in a research report on Tuesday, May 17th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $61.38.
一些券商最近加入了ZNTL的行列。SVB Leerink在8月10日(週三)的一份報告中將Zentalis PharmPharmticals的目標價從67.00美元下調至42.00美元,並對該股設定了“跑贏大盤”的評級。摩根士丹利在8月11日(週四)的一份報告中將Zentalis PharmPharmticals的目標價從95.00美元下調至60.00美元,並對該股設定了“增持”評級。考恩在7月12日星期二的一份研究報告中開始報道Zentaris製藥公司。他們對該股給予了“跑贏大盤”的評級。考恩在7月12日星期二的一份研究報告中開始報道Zentaris製藥公司。他們對該股給予了“跑贏大盤”的評級。最後,古根海姆在5月17日星期二的一份研究報告中將其對Zentalis製藥公司的目標價下調至57.00美元,並對該股設定了“NA”評級。根據MarketBeat.com的數據,9位分析師對該股的評級為買入,目前該股的普遍評級為“買入”,平均目標價為61.38美元。
Zentalis Pharmaceuticals Price Performance
Zentaris藥品價格表現
The firm has a market capitalization of $1.37 billion, a PE ratio of -6.87 and a beta of 1.88. The stock has a 50-day moving average price of $28.58 and a 200-day moving average price of $30.83.
該公司的市值為13.7億美元,市盈率為-6.87,貝塔係數為1.88。該股的50日移動均線價格為28.58美元,200日移動均線價格為30.83美元。
Insider Activity at Zentalis Pharmaceuticals
Zentalis製藥公司的內幕活動
In related news, COO Kevin D. Bunker sold 1,710 shares of the business's stock in a transaction dated Wednesday, July 13th. The stock was sold at an average price of $30.02, for a total value of $51,334.20. Following the completion of the sale, the chief operating officer now directly owns 108,290 shares of the company's stock, valued at $3,250,865.80. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other Zentalis Pharmaceuticals news, COO Kevin D. Bunker sold 5,000 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $30.00, for a total value of $150,000.00. Following the completion of the transaction, the chief operating officer now directly owns 100,000 shares in the company, valued at $3,000,000. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Kevin D. Bunker sold 1,710 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Wednesday, July 13th. The shares were sold at an average price of $30.02, for a total value of $51,334.20. Following the completion of the transaction, the chief operating officer now owns 108,290 shares of the company's stock, valued at $3,250,865.80. The disclosure for this sale can be found here. Insiders sold a total of 31,710 shares of company stock valued at $953,084 over the last three months. 19.90% of the stock is owned by insiders.
在相關新聞中,首席運營官凱文·D·邦克在一筆日期為7月13日星期三的交易中出售了1,710股該公司股票。這隻股票的平均售價為30.02美元,總價值為51334.20美元。出售完成後,首席運營官現在直接擁有公司股票108,290股,價值3,250,865.80美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,用户可以通過以下鏈接訪問該文件。在Zentalis製藥公司的其他消息中,首席運營官Kevin D.Bunker在7月20日星期三的一筆交易中出售了5000股Zentalis製藥公司的股票。這隻股票的平均售價為30.00美元,總價值為15萬美元。交易完成後,首席運營官現在直接擁有該公司10萬股,價值300萬美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,通過這個超級鏈接可以訪問微博。此外,在7月13日星期三的一次交易中,首席運營官凱文·D·邦克出售了1,710股Zentalis製藥公司的股票。這些股票的平均價格為30.02美元,總價值為51,334.20美元。交易完成後,首席運營官現在擁有該公司108,290股股票,價值3,250,865.80美元。此次拍賣的披露信息可在此處找到。過去三個月,內部人士總共出售了31,710股公司股票,價值953,084美元。19.90%的股份由內部人士持有。
Hedge Funds Weigh In On Zentalis Pharmaceuticals
對衝基金買入Zentalis製藥公司股票
A number of hedge funds and other institutional investors have recently bought and sold shares of ZNTL. Matrix Capital Management Company LP boosted its stake in Zentalis Pharmaceuticals by 111.5% in the second quarter. Matrix Capital Management Company LP now owns 9,199,973 shares of the company's stock valued at $258,519,000 after acquiring an additional 4,850,694 shares during the period. Decheng Capital Management III Cayman LLC acquired a new position in shares of Zentalis Pharmaceuticals during the second quarter worth approximately $51,271,000. State Street Corp lifted its position in Zentalis Pharmaceuticals by 50.0% in the second quarter. State Street Corp now owns 3,119,734 shares of the company's stock worth $87,665,000 after purchasing an additional 1,039,294 shares during the period. FMR LLC lifted its position in Zentalis Pharmaceuticals by 15.3% in the second quarter. FMR LLC now owns 7,776,168 shares of the company's stock worth $218,510,000 after purchasing an additional 1,033,474 shares during the period. Finally, Perceptive Advisors LLC acquired a new stake in Zentalis Pharmaceuticals in the fourth quarter worth approximately $36,192,000.
一些對衝基金和其他機構投資者最近買賣了ZNTL的股票。MATRIX資本管理公司LP在第二季度增持了111.5%的Zentalis製藥股份。在此期間,Matrix Capital Management Company LP增持了4,850,694股股票,目前擁有該公司9,199,973股股票,價值258,519,000美元。德成資本管理III開曼有限責任公司在第二季度收購了Zentalis製藥公司的新股票,價值約51,271,000美元。道富集團在第二季度將其在Zentalis PharmPharmticals的頭寸提高了50.0%。道富銀行目前持有3,119,734股該公司股票,價值87,665,000美元,在此期間又購買了1,039,294股。FMR LLC在第二季度將其在Zentalis製藥公司的頭寸提高了15.3%。在此期間,FMR LLC又購買了1,033,474股,現在擁有7,776,168股該公司股票,價值218,510,000美元。最後,感知顧問公司在第四季度收購了Zentalis製藥公司價值約36,192,000美元的新股份。
About Zentalis Pharmaceuticals
關於Zentaris製藥公司
(Get Rating)
(獲取評級)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.
Zentalis製藥公司是一家臨牀階段的生物製藥公司,專注於發現和開發用於治療各種癌症的小分子療法。它的主要候選產品包括WEE1的抑制劑ZN-c3,這是一種蛋白質酪氨酸激酶,正處於治療晚期實體腫瘤的第二階段臨牀試驗;作為單一療法治療晚期實體腫瘤的第1/2階段臨牀試驗,以及正在進行的與鉑耐藥卵巢癌患者的聯合化療的1b階段臨牀試驗;以及腫瘤不可知的、可預測的生物標記物的第二階段單一治療試驗。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Zentalis Pharmaceuticals (ZNTL)
- Is Lyft Going To Make It As Acquisition Rumors Swirl?
- Can Health Drink Maker Celsius Outrun Its Monster Rival?
- It's Time To Embrace Another 25% Decline In The S&P 500
- Four Cheap Stocks With Interesting Insider Activity
- Is Five Below Trying to Punch Too High?
- 免費獲取StockNews.com關於Zentalis製藥的研究報告(ZNTL)
- 隨着收購傳言的甚囂塵上,Lyft能否成功?
- 健康飲料製造商Celsius能否超越其Monster競爭對手?
- 現在是時候接受標準普爾500指數再下跌25%的時候了
- 具有有趣內幕活動的四隻廉價股票
- 下面的五個是不是打得太高了?
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Zentaris製藥日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Zentalis製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。